Reporting on norepinephrine dosage has been inconsistent due to variations in how drug labels account for different salt formulations. This inconsistency creates problems in clinical practice and research by making it difficult to accurately compare data across studies.

This paper reviewed the history of norepinephrine dose reporting to understand the evolution of this issue and identify ways to standardize it.

By systematically analyzing existing literature, the review traces the progression of this problem and highlights how dose variability affects patient care and research integrity.

The review points to national initiatives, like the U.S. Salt Policy and a similar model in France, as potential frameworks for achieving global harmonization. Achieving worldwide consistency in norepinephrine dose reporting is essential for designing effective clinical trials, synthesizing evidence correctly, and ultimately improving patient outcomes.

Read More